IGC Announces Continued Educational Initiatives in Support of Hyalolex
April 22 2019 - 07:00AM
Business Wire
India Globalization Capital, Inc. (NYSE: IGC) announces that it
will host educational conferences in two of the largest cities in
Puerto Rico on April 27, 2019 (San Juan) and April 28, 2019 (Ponce)
from 9:00 a.m. to 5:00 p.m. each day. These full-day events will
feature presentations for physicians in the morning and provide
programs tailored to technicians, patients, and caregivers in the
afternoon. These events are part of a series of educational
initiatives IGC is hosting in support of Hyalolex™, the Company’s
cannabinoid-based product designed to help improve the lives of
patients suffering from Alzheimer’s disease, as well as improve the
lives of caregivers.
The Company previously hosted an educational conference on
Saturday, March 30, 2019, in San Juan. This full-day event was
similarly organized as a forum for distinguished speakers,
including cannabis educators and a quality of life specialist, to
address managing Alzheimer’s disease with Cannabinoids. The
conference featured a variety of informative presentations and
workshops and was attended by an estimated 200 individuals,
including physicians, industry insiders, patients, and their
caregivers.
By hosting these conferences, the Company obtains direct
feedback from physicians, patients, caregivers, and the owners of
dispensaries. According to data from alz.org, there are
approximately 5.8 million individuals in the U.S. with Alzheimer’s
dementia in 2019 with a projected cost to the U.S. health care
system of $290 billion. Estimates suggest that the cost by 2050
will approach $1.1 trillion in 2019 dollars. There is no cure for
Alzheimer’s disease.
The IGC formulation delivers micro doses of cannabinoids with
the goal of helping to manage Alzheimer’s -related symptoms such as
anxiety, aggression, and sleep disorder, and it is intended to
provide improvement in the quality of life for patients. One
particular aspect that we hope to address is that of caregiver
distress. The Company proposes to conduct clinical trials as part
of its strategy to develop pharmaceutical products.
“The launch of Hyalolex™ in a smaller controlled environment
like Puerto Rico allows us to develop and refine a market
penetration strategy and financial model for the product that can
then be scaled to other parts of the country that possess
significantly larger addressable Alzheimer’s populations,” stated
Ram Mukunda, CEO
As previously reported, the current MSRP for a 30 ml bottle of
Hyalolex™ is $55.00. For more information about Hyalolex™, visit
www.hyalolex.com.
About IGC:
IGC has two lines of business: infrastructure and
hemp/cannabinoid derived products. The company is based in
Maryland, U.S.A. Our website: www.igcinc.us.Twitter @IGCIR
Forward-looking Statements:
This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
These forward-looking statements are based largely on IGC’s
expectations and are subject to a number of risks and
uncertainties, certain of which are beyond IGC’s control. Actual
results could differ materially from these forward-looking
statements as a result of, among other factors, competitive
conditions in the industries in which IGC operates, failure to
commercialize one or more of the technologies of IGC, general
economic conditions that are less favorable than expected, and
other factors, many of which are discussed in our SEC filings. In
light of these risks and uncertainties, there can be no assurance
that the forward-looking information contained in this release will
in fact occur.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190422005259/en/
Claudia Grimaldi301-983-0998
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Feb 2024 to Mar 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Mar 2023 to Mar 2024